You just read:

Sanofi's Investigational Semuloparin in Cancer Patients Initiating Chemotherapy Shows a 64 % Risk Reduction in Life-Threatening Venous Thrombo-Embolism

News provided by

Sanofi

04 Jun, 2011, 13:00 BST